```html

Zollinger‑Ellison‑type Gastritis

What is Zollinger‑Ellison‑type gastritis?

Zollinger‑Ellison‑type gastritis is a form of gastritis (inflammation of the stomach lining) that results from excessive secretion of gastric acid due to a Zollinger‑Ellison syndrome (ZES) tumor, also called a gastrinoma. Gastrinomas are neuroendocrine tumors that produce large amounts of the hormone gastrin, which in turn stimulates the parietal cells of the stomach to release acid. When gastrin levels become abnormally high, the stomach environment becomes extremely acidic, leading to erosive gastritis, ulcer formation, and a range of digestive symptoms.

While classic ZES is a rare condition (approximately 0.1–0.3 cases per 100,000 people), the downstream effect—acid‑related gastritis—can mimic more common gastritis types, making accurate diagnosis essential.

Key points:

• It is a secondary (reactive) gastritis caused by hypergastrinemia.
• Most often related to gastrin‑producing tumors (gastrinomas) located in the pancreas or duodenum.
• Excess acid can overwhelm the stomach’s protective mucus, leading to erosion and ulceration.

Common Causes

Although the term “Zollinger‑Ellison‑type gastritis” specifically refers to gastritis driven by gastrinoma‑induced hyperacidity, several conditions can produce a similar pathophysiology by raising gastrin levels or acid output. The most frequent causes include:

• Gastrinoma (Zollinger‑Ellison syndrome) – a neuroendocrine tumor of the pancreas or duodenum.
• Duodenal ulcer disease – chronic ulcers stimulate gastrin release via feedback loops.
• Chronic atrophic gastritis with auto‑immune gastrin elevation – loss of parietal cells leads to compensatory hypergastrinemia.
• Proton‑pump inhibitor (PPI) rebound hypergastrinemia – long‑term PPI use can cause the stomach to produce more gastrin when the medication is stopped.
• Helicobacter pylori infection – especially when the infection involves the antrum, it may increase gastrin production.
• Renal insufficiency – reduced clearance of gastrin results in higher circulating levels.
• Somatostatin‑deficient states (e.g., after pancreatic surgery) – loss of the inhibitory hormone somatostatin raises gastrin.
• MEN1 (Multiple Endocrine Neoplasia type 1) syndrome – patients frequently develop gastrinomas as part of the syndrome.
• Vagotomy or other gastric surgeries – disrupt normal feedback and may cause hypergastrinemia.
• Rare gastrin‑secreting neuroendocrine tumors outside the pancreas/duodenum – e.g., bronchial carcinoids.

Associated Symptoms

Because the hallmark of Zollinger‑Ellison‑type gastritis is extreme acid production, the symptom profile mirrors that of severe peptic ulcer disease but often appears earlier and is more persistent.

• Burning epigastric pain that may improve with food (unlike typical ulcer pain) or persist despite antacids.
• Recurrent or multiple duodenal ulcers; ulcer disease that does not heal with standard therapy.
• Diarrhea or watery stools – excess acid inactivates pancreatic enzymes and damages intestinal mucosa.
• Steatorrhea (fatty, foul‑smelling stools) due to malabsorption.
• Nausea and occasional vomiting, sometimes with a sour or bitter taste.
• Weight loss despite normal or increased appetite.
• Gastro‑esophageal reflux symptoms (heartburn, regurgitation).
• Upper abdominal fullness or bloating.
• Iron‑deficiency anemia – chronic bleeding from erosions can cause occult blood loss.

When to See a Doctor

Prompt medical evaluation is crucial if you notice any of the following:

• Persistent abdominal pain that lasts longer than 2 weeks.
• Repeated episodes of diarrhea or greasy stools.
• Unexplained weight loss of >5 % of body weight over a month.
• Vomiting blood (hematemesis) or black, tarry stools (melena).
• Symptoms that do not improve with over‑the‑counter antacids or PPIs.
• Family history of MEN1 or known gastrinomas.

Early assessment can prevent complications such as perforated ulcers, severe bleeding, or pancreatic cancer associated with MEN1.

Diagnosis

Diagnosing Zollinger‑Ellison‑type gastritis involves confirming hypergastrinemia, ruling out other causes, and locating the gastrinoma if present.

1. Laboratory Tests

• Fasting serum gastrin level – Values > 1000 pg/mL are highly suggestive of gastrinoma; levels > 200 pg/mL with a low gastric pH are also diagnostic.
• Secretin stimulation test – In gastrinoma, gastrin paradoxically rises after IV secretin.
• Basic metabolic panel – assesses renal function, which can influence gastrin levels.
• Complete blood count – looks for anemia from chronic bleeding.
• Helicobacter pylori testing (urea breath test, stool antigen, or biopsy).

2. Endoscopic Evaluation

• Upper endoscopy (EGD) – visualizes erosive gastritis, multiple duodenal ulcers, and allows biopsies to exclude malignancy.
• Biopsy specimens are examined for H. pylori, neoplastic changes, and the degree of inflammation.

3. Imaging Studies to Locate Tumors

• CT scan (multiphase abdomen) – detects pancreatic or duodenal masses.
• Endoscopic ultrasound (EUS) – highly sensitive for small (< 1 cm) gastrinomas.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – identifies neuroendocrine tumor tissue throughout the body.

4. Additional Tests (if needed)

• 24‑hour gastric pH monitoring – confirms hyperacidity.
• Genetic testing for MEN1 mutations in patients with a family history or multiple endocrine neoplasias.

Treatment Options

Treatment is two‑fold: control the acid hypersecretion and address the underlying tumor (if present).

Acid‑Suppressive Therapy

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 20–80 mg daily or equivalent; they are the cornerstone for symptom control.
• Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan, which can provide rapid and profound acid suppression.
• Therapy is usually lifelong unless the gastrinoma is cured surgically.

Surgical Management of Gastrinoma

• Curative resection – en‑bloc removal of localized tumors (often pancreaticoduodenectomy or limited duodenal excision).
• Debulking surgery – for metastatic disease, to reduce tumor burden and lower gastrin output.
• In selected patients, laparoscopic or robotic approaches are feasible.

Medical Therapy for Unresectable or Metastatic Tumors

• Somatostatin analogs (octreotide or lanreotide) – inhibit gastrin release and can shrink tumor size.
• Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.

Adjunctive & Home Care Measures

• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which exacerbate mucosal injury.
• Eat small, frequent meals; limit spicy, fatty, and acidic foods that can aggravate symptoms.
• Stay hydrated; replace electrolytes if chronic diarrhea is present.
• Maintain a balanced diet rich in iron and vitamin B12 to counteract anemia.
• Quit smoking and limit alcohol intake – both increase acid secretion and impair mucosal healing.

Prevention Tips

While a gastrinoma cannot be prevented, several strategies can reduce the risk of severe gastritis and its complications:

• Promptly treat H. pylori infection – eradication lowers gastrin levels and ulcer risk.
• Use PPIs or H2 blockers only under physician guidance; avoid abrupt discontinuation to prevent rebound hypergastrinemia.
• Regular screening for patients with MEN1 or a family history of neuroendocrine tumors.
• Limit or avoid NSAIDs, especially if you have a history of ulcer disease.
• Adopt a diet low in processed fats and high in fiber, which supports overall gastrointestinal health.
• Monitor kidney function if you have chronic renal disease, as reduced clearance can raise gastrin.

Emergency Warning Signs

Key Take‑aways

Zollinger‑Ellison‑type gastritis is a serious, acid‑related inflammation of the stomach caused primarily by gastrin‑secreting tumors. Early recognition, proper laboratory and imaging work‑up, and aggressive acid suppression are essential. When a gastrinoma is present, surgical removal combined with medical therapy offers the best chance for long‑term control.

Because the condition can mimic more common forms of gastritis, patients with persistent, severe ulcer symptoms—especially those unresponsive to standard therapy—should discuss the possibility of a gastrinoma with their healthcare provider.

References:

• Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org. Accessed April 2026.
• National Institutes of Health (NIH) – National Institute of Diabetes and Digestive and Kidney Diseases. “Gastrinoma (Zollinger‑Ellison Syndrome).” niddk.nih.gov.
• American College of Gastroenterology. “Management of Gastric Acid Hypersecretion.” gi.org.
• Wollin, D. et al. “Somatostatin analogues in the treatment of Zollinger‑Ellison syndrome.” *Journal of Clinical Endocrinology & Metabolism*, 2022.
• World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, 5th Edition, 2024.

```